ALEXION REPORTS SOLIRIS DATA

A A

Alexion hasreported positive preliminary six month interim results from SHEPHERD, its second Phase III trial testing Soliris (eculizumab) in a broader population of paroxysmal nocturnal hemoglobinuria (PNH) patients.

SHEPHERD is an open-label, non-placebo controlled 12 month Phase III PNH study which is primarily focused on examining safety, as well as efficacy measures. Interim results show that Soliris (eculizumab) appeared to be safe and well-tolerated.